Early trial aims to tame tough cancers with Two-Pronged attack
NCT ID NCT03725436
Summary
This early-stage study is testing a new drug, ALRN-6924, combined with a standard chemotherapy (paclitaxel) for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest and most effective dose of this combination and to see what side effects it causes. The trial is specifically for patients whose tumors have a normal version of a gene called TP53, including a group with a common type of breast cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.